Carotid Stenosis and TAVR

Aortic Stenosis affects over 5% of the population over 65. 

Estenosis carotídea y TAVI

Even though TAVR has advanced in the treatment of this disease, many patients present carotid aortic stenosis (CAS), which involves additional surgical risk. This risk has not been thoroughly assessed in the context of TAVR. 

A meta-analysis was carried out including 5 observational studies with a total 111,915 patients. Mean patient age was 83 and 46% were women.

Stroke or transient ischemic attack (TIA) rate was higher in patients presenting CAS (OR 1.44; CI 95% 1.07–1.95; p = 0.016), with no significant differences in myocardial infarction (OR 1.24; CI 95% 1.05–1.47; p = 0.074), all-cause mortality (OR 0.99; CI 95% 0.71–1.37; p = 0.94), acute kidney failure (OR 0.98; CI 95% 0.90–1.06) and the need for pacemaker implantation after TAVR (OR 0.95; CI 95% 0.70–1.30; p = 0.759) between both groups.

Conclusión

This analysis revealed a link between carotid stenosis and cerebrovascular events in patients undergoing TAVR, with no significant impact on all-cause mortality. We highlight the need for prospective studies for a more detailed assessment of additional determinants of this association, such as unilateral or bilateral compromise and stenosis degree, which increases risk. 

Original Title: Impact of carotid artery stenosis on outcomes of transcatheter aortic valve replacement: A systematic review and meta-analysis.

Reference: Lucas Caetano da Silva, et al. International Journal of Cardiology, https://doi.org/10.1016/j.ijcard.2023.131670.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...